NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm

BETHESDA, Md., Oct. 17, 2017 /PRNewswire/ — Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced…Read More »

NW BIO Announces Registered Direct Offering Of $1.75 Million

BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ — Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announce…Read More »

ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017

Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance an…Read More »

DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO)…Read More »

Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers…Read More »

Forward Looking Statements

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the use of proceeds; the exercise of the Overallotment Right and the satisfaction of customary closing conditions for such exercise; the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

This Blog is official and sanctioned by Northwest Biotherapeutics | See Disclaimer | See Privacy Policy

Get Northwest Biotherapeutics Blog Post Alerts